Novonesis AS

AGM Information • Feb 26, 2014

February 26, 2014

Today Novozymes A/S held its Annual Shareholders' Meeting. The following were approved:

• The audited Novozymes Report for the fiscal year 2013
• Distribution of profit in accordance with The Novozymes Report for 2013 with payment of a dividend of DKK 2.50 per share of DKK 2, an increase of 14% compared with 2012
• Remuneration of the Board of Directors for 2014
• Election of Henrik Gürtler as Chairman and Agnete Raaschou-Nielsen as Vice Chairman of the Board of Directors
• Re-election of Lena Olving, Jørgen Buhl Rasmussen and Mathias Uhlén as members of the Board of Directors
• Election of Lars Green as member of the Board of Directors
• Re-election of PricewaterhouseCoopers as the company's auditor
• The Board of Director's other proposals, hereunder: Proposal from the Board of Directors that the annual report of 2013 and future annual reports shall be prepared in English unless the Board of Directors determines that the annual report shall be prepared in Danish as well

Following the Annual Shareholders' Meeting, the Board of Directors consists of the following members:

• Henrik Gürtler, CEO of Novo A/S (Chairman)
• Agnete Raaschou-Nielsen, Chairman of the Board of Brdr. Hartmann A/S (Vice Chairman)
• Lena Olving, CEO of Micronic Mydata AB (Sweden)
• Jørgen Buhl Rasmussen, CEO of Carlsberg A/S
• Lars Green, Senior Vice President, Novo Nordisk A/S (Chairman of the Audit Committee)
• Mathias Uhlén, Professor, Kungliga Tekniske Högskolan (Sweden)
• Lena Bech Holskov, Safety Adviser (employee representative)
• Anders Hentze Knudsen, Senior Operator (employee representative)
• Lars Bo Køppler, Technician (employee representative)

For further information on members of the Board of Directors, go to www.novozymes.com.

Company announcement No. 24, 2014 Page 1 of 2

Contact information

Investor Relations:
Thomas Bomhoff (DK)	+45 3077 1226	tsbm@novozymes.com
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com
Press and media:
Rene Tronborg (DK)	+45 3077 2274	retr@novozymes.com
Frederik Bjoerndal (Europe)	+45 3077 0236	tfbh@novozymes.com
Paige Donnelly (USA)	+1 919 218 4501	pagd@novozymes.com
Meng Lian (China)	+86 136 9923 1164	mexl@novozymes.com
Henrique Pellini (Brazil)	+55 41 9288 0282	hqp@novozymes.com
Poonam Kapila (India)	+91 991 082 2339	poka@novozymes.com

This company announcement contains forward-looking statements. Forward-looking statements are, by their very nature, associated with risks and uncertainties that may cause actual results to differ materially from expectations. The uncertainties may include unexpected developments in the international currency exchange and securities markets, market-driven price decreases for Novozymes' products, and the launch of competing products in Novozymes' core areas.

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com